<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660868</url>
  </required_header>
  <id_info>
    <org_study_id>EK157072007</org_study_id>
    <nct_id>NCT00660868</nct_id>
  </id_info>
  <brief_title>Is Pentoxifylline Able to Improve Olfactory Sensitivity?</brief_title>
  <official_title>Agapurin Retard Used in Patients With Smell Disorder- A Post-marketing Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Signal processing in the olfactory neuron could be influenced by inhibition of enzymes like
      phosphodiesterase. Pentoxifylline is a unspecific phosphodiesterase inhibitor. The hypothesis
      is that pentoxifylline could lead to increased sensitivity to odors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Olfactory signal processing is conducted by a G-protein linked increase of intracellular
      concentration of adenosine 3´,5´-cyclic monophosphate (cAMP). In the cilia of olfactory
      sensory neurons (OSN) cAMP is degraded by phosphodiesterase 1C2 (PDE1C2). Inhibition of
      PDE1C2 could result in an increased response of OSN to chemical stimuli. Aim of the present
      prospective post-marketing surveillance study was to investigate the impact of
      pentoxifylline, an unspecific phosphodieasterase inhibitor, on olfactory function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>TDI-score</measure>
    <time_frame>at day 0 and follow up after 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>odor threshold odor discrimination odor identification</measure>
    <time_frame>at day 0 and at follow up after 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">7</enrollment>
  <condition>Olfaction Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with posttraumatic, idiopathic, and postinflammatory cause of smell loss; patients age between 18 and 50 years. Odor threshold better than 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline retard 400mg</intervention_name>
    <description>Agapurin retard 400mg 3/day per os for 3 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Agapurin retard</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        hyposmic or functionally anosmic patients TDI-score &lt;31; age: 18-50 years; odor threshold:
        better than 1; cause of smell loss: post traumatic, postinflammatory, idiopathic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hyposmic or functionally anosmic patients TDI-score &lt;31

          -  age: 18-50 years

          -  odor threshold: better than 1

          -  cause of smell loss: post traumatic, postinflammatory, idiopathic

        Exclusion Criteria:

          -  normosmic patients,

          -  patients with contraindications for application of pentoxifylline

          -  patients that cannot give written agreement to the study

          -  patients under 18 years and over 50 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Gudziol, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentrum für Riechen und Schmecken, Universitäts- HNO- Klinik Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smell</keyword>
  <keyword>olfaction</keyword>
  <keyword>olfactory sensitivity</keyword>
  <keyword>smell loss</keyword>
  <keyword>chemoreception</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olfaction Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

